^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Pancreatic Cancer

    Related cancers:
    16h
    Research on Comprehensive Pedigree Analysis of the Tumor Microenvironment (ChiCTR2600118636)
    P=N/A, N=785, Shandong Provincial Qianfoshan Hospital; Shandong Provincial Qianfoshan Hospital
    New trial
    17h
    Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=36, Recruiting, Emory University | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    17h
    Comprehensive Staging System for Postoperative Stratification of Pancreatic Ductal Adenocarcinoma (ChiCTR2600118611)
    P=N/A, N=500, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New trial
    17h
    Validation Study of a CT-Based Target Prediction Model for Pancreatic Cancer (ChiCTR2600118434)
    P=N/A, N=0, Fudan University Shanghai Cancer Center; Department of Pancreatic Surgery
    New trial
    18h
    Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer (ChiCTR2600118275)
    P=N/A, N=400000, ShangHai ChangHai Hospital; ShangHai ChangHai Hospital
    New trial
    18h
    Deep learning model based on ultrasound images for early differential diagnosis of pancreatic tumors (ChiCTR2600118220)
    P=N/A, N=0, Completed, The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology
    New trial
    18h
    Research on a Deep Learning Model for Gene Mutation Prediction Based on Histopathological Images in Pancreatic Cancer (ChiCTR2600118208)
    P=N/A, N=0, Fudan University Shanghai Cancer Center; Department of Pancreatic Surgery
    New trial
    18h
    Construction and Validation of a Machine Learning-Based Risk Prediction Model for Emotional Distress in Cancer Patients (ChiCTR2600118103)
    P=N/A, N=2500, Recruiting, Tianjin Medical University Cancer Institute & Hospital; Tianjin Medical University Cancer Institute & Hospital
    New trial
    19h
    2138-CL-0101: A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer (clinicaltrials.gov)
    P1, N=398, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: May 2027 --> May 2028 | Trial primary completion date: Nov 2026 --> May 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CA 19-9 (Cancer antigen 19-9)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • paclitaxel • 5-fluorouracil • capecitabine • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • ASP2138
    20h
    Intracavitary Infusion of Adebrelimab combined with the best standard treatment for the Treatment of Pancreatic Cancer with Pleural and Peritoneal Effusions: A Single-center, Prospective, Clinical Trial (ChiCTR2600118379)
    P=N/A, N=20, Recruiting, Eastern Theater General Hospital of the Chinese People's Liberation Army; Eastern Theater General Hospital of the Chinese People's Liberation Army
    New trial
    |
    AiRuiLi (adebrelimab)
    1d
    Pre-operative Treatment for Patients With Untreated Pancreatic Cancer (clinicaltrials.gov)
    P2, N=40, Completed, HonorHealth Research Institute | Active, not recruiting --> Completed | N=24 --> 40 | Trial completion date: Aug 2025 --> Nov 2025
    Trial completion • Enrollment change • Trial completion date
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    1d
    PDK4 acts via hippo signaling to inhibit ferroptosis and reduce gemcitabine sensitivity in pancreatic cancer. (PubMed, J Mol Histol)
    Expression of glutathione peroxidase 4 and acyl-CoA synthetase long-chain family 4 and Hippo signaling proteins, TAZ and YAP, were also altered. PDK4 influenced ferroptosis in pancreatic cancer cells via an effect on Hippo signaling with implications for gemcitabine resistance.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4) • PDK4 (Pyruvate Dehydrogenase Kinase 4)
    |
    gemcitabine